Abstract：OBJECTIVE: To develop an experimental rat model of inflammatory bowel disease (IBD) by administration of dextran sulfate sodium (DSS), and to observe changes in the tight junction protein expression and permeability of colon mucosa. METHODS: Male Sprague-Dawley (SD) rats were randomly divided into control (n=27) and IBD model groups (n=27). In the IBD model group, IBD was induced by 6-day administration of 3% DSS in water followed by 14-day administration of water only. The control group was fed with water only. Pathological changes in colon mucosae were observed on days 7, 14 and 21 after DSS administration. Colon tissue specimens were collected on day 21 for measuring myeloperoxidase (MPO) activity. The transepithelial electric resistance (TEER), transepithelial potential difference (TEPD) and short circuit current (Isc) of the specimens were measured by Ussing chamber. Real-time PCR and Western blot were used to measure the mRNA and protein expression of tight junction proteins in colon epithelia. RESULTS: In the IBD model group, diarrhea, hemafecia and weight loss were seen. Inflammation occurred mainly in the distal colon and was characterized by crypt abscess and inflammatory cell infiltration. The IBD model group showed significantly increased MPO activity (P<0.01), significantly decreased TEER (P<0.01) and TEPD (P<0.01), and significantly increased Isc (P<0.01) compared with the control group. No claudin 2 expression of mRNA and protein was detected in the control group, and they were expressed in the IBD model group. The expression levels of claudin 3, occludin and ZO-1 in the IBD model group were significantly decreased compared with in the control group (P<0.01). CONCLUSIONS: IBD rats show colonic barrier dysfunction and changes in the expression of tight junction proteins. The changes in the expression of tight junction proteins may contribute to colonic barrier dysfunction in cases of IBD in the chronic recovery stage.
RAO Yan-Xia,CHEN Jie,CHEN Lei-Lei et al. Changes in tight junction protein expression and permeability of colon mucosa in rats with dextran sulfate sodium-induced inflammatory bowel disease[J]. CJCP, 2012, 14(12): 976-981.
［1］Chen Y, Si JM, Liu WL, Cai JT, Du Q, Wang LJ, et al. Induction of experimental acute ulcerative colitis in rats by administration of dextran sulfate sodium at low concentration followed by intracolonic administration of 30% ethanol［J］. J Zhejiang Univ Sci B, 2007, 8(9): 632-637.
［2］Mennigen R, Bruewer M. Effect of probiotics on intestinal barrier function［J］. Ann N Y Acad Sci, 2009, 1165: 183-189.
［3］Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice［J］. Gastroenterology, 1990, 98(3): 694-702.
［4］Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis［J］. Lab Invest, 1993, 69(2): 238-249.
［5］Irvine EJ, Marshall JK. Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk［J］. Gastroenterology, 2000, 119(6): 1740-1744.
［6］Kullmann F, Messmann H, Alt M, Gross V, Bocker T, Sch-lmerich J, et al. Clinical and histopathological features of dextran sulfate sodium induced acute and chronic colitis associated with dysplasia in rats［J］. Int J Colorectal Dis, 2001, 16(4): 238-246.
［7］Solomon L, Mansor S, Mallon P, Donnelly E, Hoper M, Loughrey M, et al. The dextran sulphate sodium (DSS) model of colitis: an overview［J］. Comp Clin Pathol, 2010, 19(3): 235-239.
［8］Whittem CG, Williams AD, Williams CS. Murine Colitis modeling using Dextran Sulfate Sodium (DSS)［J］. J Vis Exp, 2010, 35: 6-8.
［9］Sutton SC, Forbes AE, Cargill R, Hochman JH, LeCluyse EL. Simultaneous in vitro measurement of intestinal tissue permeability and transepithelial electrical resistance (TEER) using Sweetana-Grass diffusion cells［J］. Pharm Res, 1992, 9(3): 316-319.
［10］Ewe K. Intestinal transport in constipation and diarrhoea［J］. Pharmacology, 1988, 36(Suppl 1): 73-84.
［11］Diehl KH, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D, et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes［J］. J Appl Toxicol, 2001, 21(1): 15-23.
［12］Zeissig S, Bojarski C, Buergel N, Mankertz J, Zeitz M, Fromm M, et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment［J］. Gut, 2004, 53(9): 1295-1302.
［13］Shimizu T, Kitamura T, Suzuki M, Fujii T, Shoji H, Tanaka K, et al. Effects of alpha-linolenic acid on colonic secretion in rats with experimental colitis［J］. J Gastroenterol, 2007, 42(2): 129-134.
［14］Bruewer M, Samarin S, Nusrat A. Inflammatory bowel disease and the apical junctional complex［J］. Ann N Y Acad Sci, 2006, 1072: 242-252.
［15］Lapierre LA. The molecular structure of the tight junction［J］. Adv Drug Deliv Rev, 2000, 41(3): 255-264.
［16］Madara JL. Regulation of the movement of solutes across tight junctions［J］. Annu Rev Physiol, 1998, 60: 143-159.
［17］Balda MS, Whitney JA, Flores C, Gonzalez S, Cereijido M, Matter K. Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein［J］. J Cell Biol, 1996, 134(4): 1031-1049.
［18］Oshima T, Miwa H, Joh T. Changes in the expression of claudins in active ulcerative colitis［J］. J Gastroenterol Hepatol, 2008, 23(Suppl 2): S146-S150.
［19］Saitou M, Fujimoto K, Doi Y, Itoh M, Fujimoto T, Furuse M, et al. Occludin-deficient embryonic stem cells can differentiate into polarized epithelial cells bearing tight junctions［J］. J Cell Biol, 1998, 141(2): 397-408.
［20］Turksen K, Troy TC. Barriers built on claudins［J］. J Cell Sci, 2004, 117(Pt 12): 2435-2447.
［21］Amasheh S, Fromm M, Günzel D. Claudins of intestine and nephron-a correlation of molecular tight junction structure and barrier function［J］. Acta Physiol (Oxf), 2011, 201(1): 133-140.
［22］Amasheh S, Meiri N, Gitter AH, Schoneberg T, Mankertz J, Schulzke JD, et al. Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells［J］. J Cell Sci, 2002, 115(Pt 24): 4969-4976.
［23］Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton［J］. J Biol Chem, 1998, 273(45): 29745-29753.
［24］Zeissig S, Bürgel N, Günzel D, Richter J, Mankertz J, Wahnschaffe U, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease［J］. Gut, 2007, 56(1): 61-72.
［25］ Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, Koltun WA. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis［J］. J Surg Res, 2007, 140(1): 12-19.
［26］Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression［J］. Am J Pathol, 2005, 166(2): 409-419.
［27］Feighery LM, Cochrane SW, Quinn T, Baird AW, O'Toole D, Owens SE, et al. Myosin light chain kinase inhibition: correction of increased intestinal epithelial permeability in vitro［J］. Pharm Res, 2008, 25(6): 1377-1386.
［28］Edelblum KL, Turner JR. The tight junction in inflammatory disease: communication breakdown［J］. Curr Opin Pharmacol, 2009, 9(6): 715-720.
